https://www.biopharmawatch.com/news/IRON/disc-medicine-restore-pv-phase-2-results BiopharmaWatch en 2026-09-09T23:25:00.000Z Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting https://www.biopharmawatch.com/news/ACTU/actuate-present-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-09T21:00:00.000Z Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-morgan-stanley-conference BiopharmaWatch en 2026-09-09T20:30:00.000Z Phibro Animal Health Corporation to Participate in Morgan Stanley Annual Global Healthcare Conference https://www.biopharmawatch.com/news/SI/shoulder-innovations-partnership-alm-ortho BiopharmaWatch en 2026-09-09T20:24:00.000Z Shoulder Innovations Announces Exclusive Partnership with ALM Ortho to Introduce Bespoke Solution for Complex Shoulder Reconstruction Procedures https://www.biopharmawatch.com/news/LEXX/lexaria-closes-warrant-exercise-5-9-million BiopharmaWatch en 2026-09-09T20:20:03.000Z Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds https://www.biopharmawatch.com/news/COO/coopercompanies-third-quarter-2026-results BiopharmaWatch en 2026-09-09T20:17:00.000Z CooperCompanies Announces Third Quarter 2026 Results https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-q1-fiscal-2027-results BiopharmaWatch en 2026-09-09T20:15:00.000Z Kewaunee Scientific Reports Results for First Quarter of Fiscal Year 2027 https://www.biopharmawatch.com/news/BKD/brookdale-reports-august-2026-occupancy BiopharmaWatch en 2026-09-09T20:15:00.000Z Brookdale Reports August 2026 Occupancy https://www.biopharmawatch.com/news/NBTX/nanobiotix-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-09T20:15:00.000Z NANOBIOTIX Participera à la Conférence H.C. Wainwright 28th Annual Global Investment https://www.biopharmawatch.com/news/NBTX/nanobiotix-hc-wainwright-investment-conference-2026 BiopharmaWatch en 2026-09-09T20:15:00.000Z NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-presentation-hc-wainwright-conference BiopharmaWatch en 2026-09-09T20:11:00.000Z Puma Biotechnology to Present at H.C. Wainwright’s 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/PRTA/prothena-hc-wainwright-investment-conference BiopharmaWatch en 2026-09-09T20:05:00.000Z Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/ELMD/electromed-participate-hc-wainwright-ld-micro-conference BiopharmaWatch en 2026-09-09T20:05:00.000Z Electromed, Inc. to Participate in the H.C. Wainwright 28th Annual Global Investment Conference and LD Micro 20th Annual Main Event https://www.biopharmawatch.com/news/MGNX/macrogenics-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-09T20:05:00.000Z MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/IPSC/century-therapeutics-appoints-joseph-truitt-board BiopharmaWatch en 2026-09-09T20:05:00.000Z Century Therapeutics Appoints Joseph Truitt to Board of Directors https://www.biopharmawatch.com/news/DGX/apple-health-app-quest-diagnostics-labs BiopharmaWatch en 2026-09-09T20:01:00.000Z Apple Health app Users to be Able to Order Labs from Quest Diagnostics https://www.biopharmawatch.com/news/AMGN/amgen-presents-morgan-stanley-global-healthcare-conference BiopharmaWatch en 2026-09-09T20:01:00.000Z AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-attend-morgan-stanley-conference-2026 BiopharmaWatch en 2026-09-09T20:01:00.000Z Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference https://www.biopharmawatch.com/news/GNLX/genelux-olvi-vec-small-cell-lung-cancer-response BiopharmaWatch en 2026-09-09T20:01:00.000Z Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy https://www.biopharmawatch.com/news/GH/guardant-health-2026-wclc-abstracts BiopharmaWatch en 2026-09-09T19:46:00.000Z Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer https://www.biopharmawatch.com/news/NTHI/neonc-raises-15-million-phase-2a-data BiopharmaWatch en 2026-09-09T13:35:00.000Z NeOnc Raises $15 Million At Market Adding Fuel to the Strong NEO100 Data https://www.biopharmawatch.com/news/SILO/silo-pharma-nasal-innovation-forum-2026 BiopharmaWatch en 2026-09-09T13:15:00.000Z Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum https://www.biopharmawatch.com/news/SI/catalyst-orthoscience-settlement-patent-litigation BiopharmaWatch en 2026-09-09T13:06:00.000Z Catalyst OrthoScience Announces Settlement of Patent Litigation with Shoulder Innovations https://www.biopharmawatch.com/news/ASBP/aspire-lakewood-holdings-share-repurchase-program BiopharmaWatch en 2026-09-09T13:03:48.043Z Aspire-Lakewood Holdings Board Approves $10 Million Share Repurchase Program https://www.biopharmawatch.com/news/AIM/aim-immunotech-ampligen-pancreatic-cancer-update BiopharmaWatch en 2026-09-09T13:03:00.000Z AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video https://www.biopharmawatch.com/news/GERN/updated-analysis-imetelstat-myelofibrosis-soho-2026 BiopharmaWatch en 2026-09-09T13:00:00.000Z September 9, 2026 https://www.biopharmawatch.com/news/LH/great-point-partners-sells-mlm-medical-labs-labcorp BiopharmaWatch en 2026-09-09T13:00:00.000Z Great Point Partners III Sells MLM Medical Labs to Labcorp https://www.biopharmawatch.com/news/GOSS/gossamer-bio-reverse-stock-split BiopharmaWatch en 2026-09-09T13:00:00.000Z Gossamer Bio Announces 1-for-80 Reverse Stock Split https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-jefferies-conference-2026 BiopharmaWatch en 2026-09-09T13:00:00.000Z Acadia Healthcare to Participate in 2026 Jefferies Healthcare Services and Technology Conference https://www.biopharmawatch.com/news/CVS/cvs-health-project-health-20-years-free-screenings BiopharmaWatch en 2026-09-09T13:00:00.000Z CVS Health marks 20 years of free community health screening program as new survey reveals many U.S. adults still face barriers to preventive health screenings https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-september-2026-conferences BiopharmaWatch en 2026-09-09T13:00:00.000Z Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences https://www.biopharmawatch.com/news/FEMY/femasys-capexmd-partnership-fertility-access BiopharmaWatch en 2026-09-09T13:00:00.000Z Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio https://www.biopharmawatch.com/news/SCNX/scienture-presentation-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-09T12:55:00.000Z SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026 https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-breast-cancer-vaccine-bloomberg-tv BiopharmaWatch en 2026-09-09T12:35:00.000Z Anixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV https://www.biopharmawatch.com/news/TRIB/trinity-biotech-trinovium-contract-red-team-investments BiopharmaWatch en 2026-09-09T12:30:00.000Z Trinity Biotech’s Trinovium Subsidiary Signs Contract to Supply Red Team Investments with Advanced Liquid Cooling Solutions for AI Data Center Infrastructure https://www.biopharmawatch.com/news/IMNN/imunon-rd-day-2026-imnn-001-progress BiopharmaWatch en 2026-09-09T12:30:00.000Z IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-phase-1b-study-prp-2027 BiopharmaWatch en 2026-09-09T12:30:00.000Z Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027 https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-fda-clearance-ms-trials BiopharmaWatch en 2026-09-09T12:30:00.000Z Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment https://www.biopharmawatch.com/news/CTKB/sysmex-cytek-collaboration-clinical-flow-cytometry BiopharmaWatch en 2026-09-09T12:30:00.000Z Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry https://www.biopharmawatch.com/news/XERS/xeris-webinar-xp-8121-development-program BiopharmaWatch en 2026-09-09T12:30:00.000Z Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism https://www.biopharmawatch.com/news/WGS/genedx-beren-therapeutics-launch-npc-genomecomplete BiopharmaWatch en 2026-09-09T12:30:00.000Z GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C https://www.biopharmawatch.com/news/FEED/envue-medical-resumes-commercial-shipments-painshield BiopharmaWatch en 2026-09-09T12:30:00.000Z ENvue Medical Resumes U.S. Commercial Shipments of NanoVibronix PainShield® and Begins Fulfilling Open Distributor Orders https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-fda-510k-drug-screening BiopharmaWatch en 2026-09-09T12:30:00.000Z Intelligent Bio Solutions Submits FDA 510(k) Package for Intelligent Fingerprinting Drug Screening System, Seeking U.S. Market Clearance https://www.biopharmawatch.com/news/TAK/oveporexton-phase-3-narcolepsy-results BiopharmaWatch en 2026-09-09T12:24:00.000Z New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life https://www.biopharmawatch.com/news/INMD/inmode-launches-morpheus8-cool-rf-microneedling BiopharmaWatch en 2026-09-09T12:05:00.000Z InMode Advances RF Microneedling Comfort with the Launch of Morpheus8 Cool https://www.biopharmawatch.com/news/NTHI/neonc-technologies-15-million-offering BiopharmaWatch en 2026-09-09T12:00:39.000Z NeOnc Technologies Holdings, Inc. Announces Pricing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules with New and Existing Institutional Investors https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-appoints-robert-redfield-cso BiopharmaWatch en 2026-09-09T12:00:00.000Z Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer https://www.biopharmawatch.com/news/KAPA/kairos-pharma-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-09T12:00:00.000Z Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/TWST/twist-bioscience-baird-2026-conference BiopharmaWatch en 2026-09-09T12:00:00.000Z Twist Bioscience to Present at Baird 2026 Global Healthcare Conference https://www.biopharmawatch.com/news/MTVA/metavia-preclinical-findings-da-1726-waist-circumference BiopharmaWatch en 2026-09-09T12:00:00.000Z MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction https://www.biopharmawatch.com/news/ECOR/electrocore-appoints-co-ceos-joshua-lev-mike-fox BiopharmaWatch en 2026-09-09T12:00:00.000Z electroCore, Inc. Appoints Joshua Lev and Mike Fox as Co-Chief Executive Officers https://www.biopharmawatch.com/news/INMB/inmune-bio-presentation-hc-wainwright-conference BiopharmaWatch en 2026-09-09T12:00:00.000Z INmune Bio to Present at the H.C. Wainwright Global Investment Conference https://www.biopharmawatch.com/news/AKTS/aktis-oncology-september-investor-conferences BiopharmaWatch en 2026-09-09T12:00:00.000Z Aktis Oncology to Present at Upcoming September Investor Conferences https://www.biopharmawatch.com/news/INAB/in8bio-appoints-oxana-polyakova-svp-research-development BiopharmaWatch en 2026-09-09T12:00:00.000Z IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-09T12:00:00.000Z Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/ADAG/adagene-exelixis-safebody-antibody-drug-conjugate BiopharmaWatch en 2026-09-09T12:00:00.000Z Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates https://www.biopharmawatch.com/news/HUMA/humacyte-fda-authorization-symvess-shelf-life-extension BiopharmaWatch en 2026-09-09T12:00:00.000Z Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months https://www.biopharmawatch.com/news/PRQR/proqr-phase-1-study-ax-0811-investor-event-2026 BiopharmaWatch en 2026-09-09T12:00:00.000Z ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026 https://www.biopharmawatch.com/news/HELP/helus-pharma-hc-wainwright-investment-conference-2026 BiopharmaWatch en 2026-09-09T11:30:30.000Z Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-first-patient-dosed-pnoc035-study BiopharmaWatch en 2026-09-09T11:30:00.000Z Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-eocene-rebranding-eocn BiopharmaWatch en 2026-09-09T11:30:00.000Z Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol "EOCN" to Reflect its New Dawn Platform for GI Innovation https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-appoints-james-treat-cmo BiopharmaWatch en 2026-09-09T11:30:00.000Z Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer https://www.biopharmawatch.com/news/CNTX/context-therapeutics-phase-1-trial-ct-202 BiopharmaWatch en 2026-09-09T11:30:00.000Z Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202 https://www.biopharmawatch.com/news/NGEN/nervgen-rd-day-september-2026 BiopharmaWatch en 2026-09-09T11:30:00.000Z NervGen to Host Inaugural R&D Day on September 30, 2026 https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-09T11:27:00.000Z Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/ACB/aurora-appoints-executive-global-commercial-cannabis BiopharmaWatch en 2026-09-09T11:05:00.000Z Aurora Appoints Seasoned Biopharmaceutical Executive to Lead Commercial Acceleration of Global Medical Cannabis Business https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-fireside-chat-wells-fargo-conference BiopharmaWatch en 2026-09-09T11:00:52.000Z X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference https://www.biopharmawatch.com/news/CANF/can-fite-namodenoson-improvement-cirrhosis-liver-transplant BiopharmaWatch en 2026-09-09T11:00:00.000Z Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation https://www.biopharmawatch.com/news/SPTX/seaport-therapeutics-positive-results-glyphallo-trial BiopharmaWatch en 2026-09-09T11:00:00.000Z Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-phase-2-surf302-results-dabogratinib BiopharmaWatch en 2026-09-09T11:00:00.000Z Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-presentation-international-congress BiopharmaWatch en 2026-09-09T11:00:00.000Z Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society https://www.biopharmawatch.com/news/OKYO/okyo-pharma-presents-at-escrs-2026 BiopharmaWatch en 2026-09-09T11:00:00.000Z OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026 https://www.biopharmawatch.com/news/KURA/kura-oncology-launches-caspian-therapeutics-diabetes BiopharmaWatch en 2026-09-09T11:00:00.000Z Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes https://www.biopharmawatch.com/news/RZLT/rezolute-fda-review-phase-3-sunrize-study-congenital-hyperinsulinism BiopharmaWatch en 2026-09-09T11:00:00.000Z Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-positive-data-micvo-head-neck-cancer BiopharmaWatch en 2026-09-09T11:00:00.000Z Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) https://www.biopharmawatch.com/news/MSLE/satellos-announces-forazapadin-international-name BiopharmaWatch en 2026-09-09T11:00:00.000Z Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247 https://www.biopharmawatch.com/news/FATE/fate-therapeutics-encore-clinical-data-2026 BiopharmaWatch en 2026-09-09T11:00:00.000Z Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting https://www.biopharmawatch.com/news/MPLT/maplight-therapeutics-investor-conference-participation BiopharmaWatch en 2026-09-09T11:00:00.000Z MapLight Therapeutics to Participate in Upcoming Investor Conference https://www.biopharmawatch.com/news/ACTU/actuate-preclinical-data-elraglusib-ras-inhibitors BiopharmaWatch en 2026-09-09T11:00:00.000Z Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib https://www.biopharmawatch.com/news/IRD/opus-genetics-phase-1-2-trial-opgx-best1-results BiopharmaWatch en 2026-09-09T11:00:00.000Z Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027 https://www.biopharmawatch.com/news/RADX/radiopharm-rad301-positive-phase-1-trial-data BiopharmaWatch en 2026-09-09T11:00:00.000Z Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma https://www.biopharmawatch.com/news/ZOMDF/zomedica-webinar-marketing-engine-september-2026 BiopharmaWatch en 2026-09-09T10:33:51.446Z Zomedica Announces "Fourth Friday at Four" Webinar on September 25, 2026: Inside Zomedica’s Marketing Engine: How Demand Becomes Revenue https://www.biopharmawatch.com/news/CMPS/compass-pathways-comp360-phase-3-results BiopharmaWatch en 2026-09-09T10:30:00.000Z Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year https://www.biopharmawatch.com/news/HIT/health-in-tech-newsweeks-greatest-mid-market-companies-2026 BiopharmaWatch en 2026-09-09T10:30:00.000Z Health In Tech Named to Newsweek's America's Greatest Mid-Market Companies 2026 https://www.biopharmawatch.com/news/MNKD/mannkind-rose-pharma-licensing-agreement-glp1 BiopharmaWatch en 2026-09-09T10:30:00.000Z MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management https://www.biopharmawatch.com/news/TLX/telix-presents-morgan-stanley-hc-wainwright-conferences BiopharmaWatch en 2026-09-09T10:30:00.000Z Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/QAI/qscreen-ai-closing-final-tranche-private-placement BiopharmaWatch en 2026-09-09T10:15:00.000Z QScreen AI Announces Closing of Final Tranche of Non-Brokered Private Placement https://www.biopharmawatch.com/news/RVTY/revvity-acquire-human-cell-design-metabolic-disease-drug-discovery BiopharmaWatch en 2026-09-09T10:00:00.000Z Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery https://www.biopharmawatch.com/news/IDYA/first-patient-dosed-optimum-11-trial-darovasertib-crizotinib BiopharmaWatch en 2026-09-09T10:00:00.000Z IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma https://www.biopharmawatch.com/news/RDNT/radnet-presentation-morgan-stanley-healthcare-conference-2026 BiopharmaWatch en 2026-09-09T10:00:00.000Z RadNet, Inc. to Present at the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16th, 2026 https://www.biopharmawatch.com/news/RDNT/radnet-free-prostate-cancer-webinar-september-2026 BiopharmaWatch en 2026-09-09T10:00:00.000Z RadNet to Host Free Prostate Cancer Webinar on September 19, 2026 https://www.biopharmawatch.com/news/MBX/microbix-qualifies-supplier-dx-test-makers BiopharmaWatch en 2026-09-09T07:00:00.000Z Microbix Qualifies as Supplier for Five Major Dx Test-Makers Product Lines for Support of Leading IVD Manufacturers https://www.biopharmawatch.com/news/EVO/evotec-phase-1-trial-orthopoxvirus-antibodies BiopharmaWatch en 2026-09-09T06:00:00.000Z Just - Evotec Biologics Advances U.S. Department of War Antibodies Against Orthopoxvirus into Phase 1 Clinical Studies https://www.biopharmawatch.com/news/EVMN/evommune-evo756-phase-2b-results-atopic-dermatitis BiopharmaWatch en 2026-09-08T21:43:00.000Z Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis https://www.biopharmawatch.com/news/THC/tenet-upsizing-pricing-senior-notes-offering BiopharmaWatch en 2026-09-08T21:00:00.000Z Tenet Announces Upsizing and Pricing of Its $2.0 Billion Private Offering of Senior Notes https://www.biopharmawatch.com/news/APMD/apnimed-reports-q2-2026-results-corporate-update BiopharmaWatch en 2026-09-08T20:39:00.000Z Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/blog/most-crowded-drug-targets-biotech-2026 BiopharmaWatch en 2026-09-08T20:38:50.515Z The Most Crowded Drug Targets in Biotech: 19 Companies Are Chasing CD19 https://www.biopharmawatch.com/news/WRBY/warby-parker-goldman-sachs-conference-2026 BiopharmaWatch en 2026-09-08T20:30:00.000Z Warby Parker Announces Participation in the Goldman Sachs 33rd Annual Global Retailing Conference https://www.biopharmawatch.com/news/BFLY/butterfly-network-morgan-stanley-healthcare-conference-2026 BiopharmaWatch en 2026-09-08T20:30:00.000Z Butterfly Network to Participate in Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026 https://www.biopharmawatch.com/news/ZBH/zimmer-biomet-leadership-promotions-commercial-transformation BiopharmaWatch en 2026-09-08T20:30:00.000Z Zimmer Biomet Announces Americas Leadership Promotions to Accelerate Commercial Transformation https://www.biopharmawatch.com/news/IMA/imagene-bio-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-08T20:30:00.000Z ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York https://www.biopharmawatch.com/news/BKD/brookdale-present-2026-jefferies-bank-america-conference BiopharmaWatch en 2026-09-08T20:15:00.000Z Brookdale to Present at the 2026 Jefferies Healthcare Services and Technology Conference and the Bank of America Global Real Estate Conference 2026 https://www.biopharmawatch.com/news/INCR/intercure-regains-compliance-nasdaq-minimum-bid-price BiopharmaWatch en 2026-09-08T20:12:00.000Z InterCure Regains Compliance with Nasdaq Minimum Bid Price Requirement https://www.biopharmawatch.com/news/FBIO/journey-medical-september-2026-investor-conferences BiopharmaWatch en 2026-09-08T20:05:00.000Z Journey Medical Corporation to Participate in September 2026 Investor Conferences https://www.biopharmawatch.com/news/STVN/stevanato-group-investor-conferences-2023 BiopharmaWatch en 2026-09-08T20:05:00.000Z Stevanato Group to Participate in Two Upcoming Investor Conferences https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-08T20:05:00.000Z Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/BBOT/bbot-announces-bbo-8520-data-strategic-focus-nsclc BiopharmaWatch en 2026-09-08T20:05:00.000Z BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers https://www.biopharmawatch.com/news/CARL/carlsmed-announces-coo-appointment BiopharmaWatch en 2026-09-08T20:05:00.000Z Carlsmed, Inc. Announces Chief Operating Officer Appointment https://www.biopharmawatch.com/news/DERM/journey-medical-september-2026-investor-conferences BiopharmaWatch en 2026-09-08T20:05:00.000Z Journey Medical Corporation to Participate in September 2026 Investor Conferences https://www.biopharmawatch.com/news/INNV/innovage-financial-results-fiscal-year-2026 BiopharmaWatch en 2026-09-08T20:05:00.000Z InnovAge Announces Financial Results for the Fourth Quarter and Fiscal Year Ended June 30, 2026 https://www.biopharmawatch.com/news/TARA/protara-therapeutics-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-08T20:05:00.000Z Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/CAMP/camp4-therapeutics-analyst-day-cmp-002-syngap1 BiopharmaWatch en 2026-09-08T20:05:00.000Z CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026 https://www.biopharmawatch.com/news/SI/shoulder-innovations-settlement-patent-litigation-catalyst BiopharmaWatch en 2026-09-08T20:05:00.000Z Shoulder Innovations Announces Settlement of Patent Litigation with Catalyst OrthoScience https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-presentation-cantor-conference-2026 BiopharmaWatch en 2026-09-08T20:05:00.000Z Tyra Biosciences to Present at the Cantor Global Healthcare Conference https://www.biopharmawatch.com/news/BRVE/braveheart-bio-q2-2026-financial-results-update BiopharmaWatch en 2026-09-08T20:03:00.000Z Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/ALGN/align-technology-financial-conference-presentation BiopharmaWatch en 2026-09-08T20:01:00.000Z Align Technology to Speak at Upcoming Financial Conference https://www.biopharmawatch.com/news/STAA/staars-new-cfo-david-bailey-appointment BiopharmaWatch en 2026-09-08T20:01:00.000Z STAAR Surgical Names Former CEO David Bailey as Chief Commercial Officer https://www.biopharmawatch.com/news/ASND/ascendis-pharma-morgan-stanley-conference-2026 BiopharmaWatch en 2026-09-08T20:01:00.000Z Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-webcast-phase-1-micvo-update BiopharmaWatch en 2026-09-08T20:01:00.000Z Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) https://www.biopharmawatch.com/news/KROS/keros-therapeutics-share-repurchase-authorization BiopharmaWatch en 2026-09-08T20:01:00.000Z Keros Therapeutics Announces $5 Million Share Repurchase Authorization https://www.biopharmawatch.com/news/LKFT/lakefront-global-healthcare-conference-2026 BiopharmaWatch en 2026-09-08T20:01:00.000Z Lakefront presenteert op de 24e jaarlijkse Global Healthcare Conference van Morgan Stanley https://www.biopharmawatch.com/news/LKFT/lakefront-presents-morgan-stanley-healthcare-conference BiopharmaWatch en 2026-09-08T20:01:00.000Z Lakefront to Present at the Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/AHCO/adapthealth-appoints-harriss-currie-cfo BiopharmaWatch en 2026-09-08T20:00:00.000Z AdaptHealth Appoints Harriss Currie as Chief Financial Officer https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-gilead-hsv-helicase-primase BiopharmaWatch en 2026-09-08T20:00:00.000Z Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program https://www.biopharmawatch.com/news/IVA/inventiva-abstracts-paris-mash-2026 BiopharmaWatch en 2026-09-08T20:00:00.000Z Inventiva présentera plusieurs abstracts lors du Congrès Paris MASH 2026 https://www.biopharmawatch.com/news/IVA/inventiva-presents-abstracts-paris-mash-2026 BiopharmaWatch en 2026-09-08T20:00:00.000Z Inventiva to Present Multiple Abstracts at Paris MASH 2026 https://www.biopharmawatch.com/news/GH/guardant-health-americas-most-innovative-businesses BiopharmaWatch en 2026-09-08T18:38:00.000Z Business Insider Names Guardant Health One of America's Most Innovative Businesses https://www.biopharmawatch.com/news/MPH/medicure-mend-pnpo-phase-3-study-eec-2026 BiopharmaWatch en 2026-09-08T18:25:00.000Z Medicure Presents MEND-PNPO Phase 3 Study Design and Baseline Data at the 16th European Epilepsy Congress https://www.biopharmawatch.com/news/OPK/opko-health-wells-fargo-healthcare-conference-2026 BiopharmaWatch en 2026-09-08T17:55:00.000Z OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/BRKR/bruker-corporation-investor-conferences-2026 BiopharmaWatch en 2026-09-08T17:21:00.000Z Bruker Corporation to Present at Upcoming Investor Conferences https://www.biopharmawatch.com/news/CVSI/cv-sciences-federal-hemp-legislation-update BiopharmaWatch en 2026-09-08T17:00:00.000Z CV Sciences Welcomes Enactment of Federal Legislation Providing Additional Time for a Responsible, Science-Based Hemp Regulatory Framework https://www.biopharmawatch.com/news/TLRY/brewdog-leicester-tigers-partnership BiopharmaWatch en 2026-09-08T16:46:00.000Z BrewDog steigt mit einer fünfjährigen Partnerschaft mit den Leicester Tigers in den Rugby-Sport ein und bringt Punk-Energie in die Welford Road https://www.biopharmawatch.com/news/TLRY/brewdog-leicester-tigers-partnership-2026 BiopharmaWatch en 2026-09-08T16:46:00.000Z BrewDog fait son entrée dans le monde du rugby sous couvert d’un partenariat conclu pour cinq ans avec les Leicester Tigers et colore le stade de Welford Road en punk https://www.biopharmawatch.com/news/AVAV/investigation-aerovironment-board-fiduciary-duty BiopharmaWatch en 2026-09-08T16:23:00.000Z Berger Montague PC Investigates AeroVironment, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: AVAV) https://www.biopharmawatch.com/news/PTGX/protagonist-therapeutics-share-repurchase-program BiopharmaWatch en 2026-09-08T16:05:00.000Z Protagonist Therapeutics Announces $300 Million Share Repurchase Program https://www.biopharmawatch.com/news/ADUS/addus-homecare-2026-jefferies-conference BiopharmaWatch en 2026-09-08T16:00:00.000Z Addus HomeCare to Participate in the 2026 Jefferies Healthcare Services and Technology Conference https://www.biopharmawatch.com/news/PHG/philips-lumea-ipl-9900-pro-launch BiopharmaWatch en 2026-09-08T14:30:00.000Z Philips Launches Revolutionary Lumea® IPL 9900 Pro: the First At-Home Intense Pulsed Light (IPL) Hair Removal Device With Real-Time Audio Guidance That Talks to You During Treatment https://www.biopharmawatch.com/news/CSTL/sci-base-additional-order-castle-biosciences BiopharmaWatch en 2026-09-08T13:30:00.000Z SciBase receives additional order from Castle Biosciences, advancing the collaboration https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-showcase-ph1-adc-payload-platform BiopharmaWatch en 2026-09-08T13:15:00.000Z Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums https://www.biopharmawatch.com/news/LH/labcorp-acquires-mlm-medical-labs-global-expansion BiopharmaWatch en 2026-09-08T13:05:00.000Z Labcorp Acquires MLM Medical Labs, Expanding Global Central Laboratory and Biomarker Capabilities for Clinical Trials https://www.biopharmawatch.com/news/AMGN/imdeltra-imfinzi-overall-survival-small-cell-lung-cancer BiopharmaWatch en 2026-09-08T13:00:00.000Z IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER https://www.biopharmawatch.com/news/ASBP/aspire-biopharma-name-change BiopharmaWatch en 2026-09-08T13:00:00.000Z Aspire Biopharma Holdings, INC. Announces Corporate Name Change To Aspire-Lakewood Holdings, Inc. https://www.biopharmawatch.com/news/SRPT/sarepta-route-79-duchenne-scholarship-recipients-2026-2027 BiopharmaWatch en 2026-09-08T13:00:00.000Z Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year https://www.biopharmawatch.com/news/SRPT/sarepta-route-79-duchenne-scholarship-recipients-2026-2027 BiopharmaWatch en 2026-09-08T13:00:00.000Z Sarepta Therapeutics anuncia a los destinatarios de Route 79, el Programa de Becas de Duchenne, para el año académico 2026-2027 https://www.biopharmawatch.com/news/CON/concentra-appoints-tanner-newton-cfo BiopharmaWatch en 2026-09-08T13:00:00.000Z Concentra Appoints Tanner Newton Chief Financial Officer https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-morgan-stanley-conference BiopharmaWatch en 2026-09-08T13:00:00.000Z Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-08T13:00:00.000Z Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/SKIN/hydrafacial-treatment-personalization-enhancers BiopharmaWatch en 2026-09-08T13:00:00.000Z Hydrafacial Expands Treatment Personalization and Elevates Results with Two New Treatment Enhancers https://www.biopharmawatch.com/news/HCSG/chemed-corporation-jefferies-2026-conference BiopharmaWatch en 2026-09-08T13:00:00.000Z Chemed Corporation to Present at the Jefferies 2026 Healthcare Services Conference https://www.biopharmawatch.com/news/HCWB/hcw-biologics-exclusive-distribution-agreement-akron-biotech BiopharmaWatch en 2026-09-08T12:50:00.000Z HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-debt-reduction BiopharmaWatch en 2026-09-08T12:45:00.000Z Vivos Therapeutics Announces Material Debt Reduction https://www.biopharmawatch.com/news/NTHI/neonc-phase-2-data-cancer-ropes BiopharmaWatch en 2026-09-08T12:39:00.000Z NeOnc' Phase 2 Data Could Put Cancer on the Ropes https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-morgan-stanley-conference-2026 BiopharmaWatch en 2026-09-08T12:30:00.000Z CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/TPST/tempest-presents-hc-wainwright-investment-conference BiopharmaWatch en 2026-09-08T12:30:00.000Z Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-phase-2-trial-lucid-ms BiopharmaWatch en 2026-09-08T12:30:00.000Z A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-fda-qrx003-peeling-skin-syndrome BiopharmaWatch en 2026-09-08T12:30:00.000Z Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome https://www.biopharmawatch.com/news/HYFT/mindwalk-holdings-q1-fy2027-report-date BiopharmaWatch en 2026-09-08T12:30:00.000Z MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2027 on September 14, 2026 https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-appoints-dr-rob-myers-cmo BiopharmaWatch en 2026-09-08T12:30:00.000Z Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer https://www.biopharmawatch.com/news/SRZN/surrozen-ind-application-szn-8141-dme BiopharmaWatch en 2026-09-08T12:30:00.000Z Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema https://www.biopharmawatch.com/news/LFWD/lifeward-updates-investor-presentation-commercial-growth BiopharmaWatch en 2026-09-08T12:30:00.000Z Lifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy https://www.biopharmawatch.com/news/OPTH/optimi-health-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-08T12:30:00.000Z Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/BBLG/bone-biologics-expands-trial-sites BiopharmaWatch en 2026-09-08T12:30:00.000Z Bone Biologics Expands Trial Sites https://www.biopharmawatch.com/news/VCEL/vericel-presentation-morgan-stanley-conference-2026 BiopharmaWatch en 2026-09-08T12:30:00.000Z Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026 https://www.biopharmawatch.com/news/EYE/eyeglass-world-brand-refresh-vml BiopharmaWatch en 2026-09-08T12:27:00.000Z EYEGLASS WORLD REFRESHES ITS BRAND WITH VML: DEBUTING "CHANGE YOUR GLASSES. CHANGE YOUR WORLD." https://www.biopharmawatch.com/news/THC/tenet-private-offering-senior-notes-refinance BiopharmaWatch en 2026-09-08T12:22:00.000Z Tenet Announces Private Offering of Senior Notes to Refinance $1.5 Billion in Outstanding Notes https://www.biopharmawatch.com/news/CANF/can-fite-q2-2026-financial-results-clinical-progress BiopharmaWatch en 2026-09-08T12:20:00.000Z Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study https://www.biopharmawatch.com/news/VERU/veru-advances-sabizabulin-phase-2-clinical-trial BiopharmaWatch en 2026-09-08T12:17:00.000Z Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial https://www.biopharmawatch.com/news/RVMD/veru-advances-sabizabulin-phase-2-trial BiopharmaWatch en 2026-09-08T12:17:00.000Z Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial https://www.biopharmawatch.com/news/GRI/gri-bio-phase-2a-data-ers-2026 BiopharmaWatch en 2026-09-08T12:15:00.000Z GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars https://www.biopharmawatch.com/news/LEXX/lexaria-exercise-warrants-5-9-million BiopharmaWatch en 2026-09-08T12:05:41.000Z Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds https://www.biopharmawatch.com/news/LABT/lakewood-amedev-biotherapeutics-presentation-hc-wainwright-conference BiopharmaWatch en 2026-09-08T12:02:00.000Z Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/SYRE/spyre-announces-best-in-class-spy003-results-skyline-trial BiopharmaWatch en 2026-09-08T12:00:51.000Z Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations https://www.biopharmawatch.com/news/AVLN/avalyn-ap01-lung-distribution-patient-centered-trial-design BiopharmaWatch en 2026-09-08T12:00:49.000Z Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis https://www.biopharmawatch.com/news/RANI/rani-therapeutics-september-conferences BiopharmaWatch en 2026-09-08T12:00:48.000Z Rani Therapeutics to Participate in Upcoming September Conferences https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-positive-clinical-data-weight-management BiopharmaWatch en 2026-09-08T12:00:44.000Z Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management https://www.biopharmawatch.com/news/CRL/charles-river-endosafe-automated-manufacturing BiopharmaWatch en 2026-09-08T12:00:00.000Z Charles River Modernizes Endosafe® Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite https://www.biopharmawatch.com/news/A/agilent-retirement-koh-boon-hwee-appointment-glenn-boehnlein BiopharmaWatch en 2026-09-08T12:00:00.000Z Agilent Announces Retirement of Board Chair Koh Boon Hwee, Appointment of Glenn Boehnlein to Board of Directors https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-alloscope-5d-patent-issuance BiopharmaWatch en 2026-09-08T12:00:00.000Z Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform https://www.biopharmawatch.com/news/COYA/coya-therapeutics-preclinical-study-coya-303 BiopharmaWatch en 2026-09-08T12:00:00.000Z Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation https://www.biopharmawatch.com/news/HSIC/applied-biocode-henry-schein-distribution-agreement BiopharmaWatch en 2026-09-08T12:00:00.000Z Applied BioCode Announces Distribution Agreement with Henry Schein https://www.biopharmawatch.com/news/GNPX/genprex-presentation-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-08T12:00:00.000Z Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/AZTR/azitra-presentation-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-08T12:00:00.000Z Azitra, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/SNY/sanofi-keke-palmer-beyfortus-rsv-awareness BiopharmaWatch en 2026-09-08T12:00:00.000Z Sanofi and Keke Palmer team up to urge parents to help protect babies from serious RSV with BEYFORTUS® https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-appoints-philip-herman-cco BiopharmaWatch en 2026-09-08T12:00:00.000Z PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer https://www.biopharmawatch.com/news/NTLA/intellia-fda-acceptance-lonvo-z-hae BiopharmaWatch en 2026-09-08T12:00:00.000Z Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE) https://www.biopharmawatch.com/news/BIOA/bioage-labs-quell-dme-phase-2-trial-bge-102 BiopharmaWatch en 2026-09-08T12:00:00.000Z BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema https://www.biopharmawatch.com/news/MBX/mbx-biosciences-jeff-held-chief-legal-officer BiopharmaWatch en 2026-09-08T12:00:00.000Z MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-08T12:00:00.000Z Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/HCAT/health-catalyst-ceo-appointment-simeon-kohl BiopharmaWatch en 2026-09-08T12:00:00.000Z Health Catalyst Appoints Simeon Kohl as Chief Executive Officer and President https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-nasdaq-transfer-investor-conferences BiopharmaWatch en 2026-09-08T12:00:00.000Z Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences https://www.biopharmawatch.com/news/HYPD/hyperion-defi-guidance-share-repurchase-program BiopharmaWatch en 2026-09-08T12:00:00.000Z Hyperion DeFi Raises Guidance and Announces $20M Share Repurchase Program https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-08T12:00:00.000Z Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/AVLN/avalyn-participate-morgan-stanley-healthcare-conference BiopharmaWatch en 2026-09-08T12:00:00.000Z Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/AVXL/anavex-investor-call-september-2026 BiopharmaWatch en 2026-09-08T12:00:00.000Z Anavex Life Sciences to Host Investor Call on Wednesday, September 9, 2026, at 4:00 PM ET https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-08T12:00:00.000Z Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/FBIO/fortress-biotech-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-08T12:00:00.000Z Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-achieve-trial-data-presentation BiopharmaWatch en 2026-09-08T11:51:00.000Z Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-08T11:45:00.000Z TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/CMND/clearmind-yale-irb-approval-cmnd-100-trial BiopharmaWatch en 2026-09-08T11:42:00.000Z Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results https://www.biopharmawatch.com/news/CGC/canopy-growth-expands-australian-medical-cannabis-portfolio BiopharmaWatch en 2026-09-08T11:30:00.000Z Canopy Growth Broadens Australian Medical Cannabis Portfolio With New Formats and Formulations https://www.biopharmawatch.com/news/NGNE/neurogene-participate-hc-wainwright-conference BiopharmaWatch en 2026-09-08T11:30:00.000Z Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/ENGN/engene-reports-q3-2026-financial-results-business-update BiopharmaWatch en 2026-09-08T11:30:00.000Z enGene Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/VSTM/verastem-oncology-vs-7375-clinical-data BiopharmaWatch en 2026-09-08T11:30:00.000Z Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers https://www.biopharmawatch.com/news/FTH/faeth-therapeutics-virtual-kol-event-endometrial-cancer BiopharmaWatch en 2026-09-08T11:30:00.000Z Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026 https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-ceo-appointment-thomas-civik BiopharmaWatch en 2026-09-08T11:30:00.000Z Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-allonk-data-disclosures-2026 BiopharmaWatch en 2026-09-08T11:30:00.000Z Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026 https://www.biopharmawatch.com/news/NSRX/nasus-pharma-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-08T11:30:00.000Z Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/BIVI/biovie-parkinsons-phase-3-development-update BiopharmaWatch en 2026-09-08T11:30:00.000Z BioVie Announces Update to Parkinson’s Phase 3 Development Program https://www.biopharmawatch.com/news/BWAY/brainsway-deep-tms-depression-alzheimers-study-results BiopharmaWatch en 2026-09-08T11:30:00.000Z BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer’s Disease Treated with Deep TMS™ https://www.biopharmawatch.com/news/BCTX/briacell-phase-3-study-expands-msk-cancer-center BiopharmaWatch en 2026-09-08T11:30:00.000Z BriaCell’s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center https://www.biopharmawatch.com/news/CRVO/cervomed-participate-september-investor-conferences BiopharmaWatch en 2026-09-08T11:30:00.000Z CervoMed to Participate in September Investor Conferences https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-08T11:30:00.000Z Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference https://www.biopharmawatch.com/news/MDCX/medicus-pharma-precision-oncology-transformation BiopharmaWatch en 2026-09-08T11:30:00.000Z Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company https://www.biopharmawatch.com/news/GENB/generate-biomedicines-september-investor-conferences BiopharmaWatch en 2026-09-08T11:09:00.000Z Generate Biomedicines Inc. to Participate in September Investor Conferences https://www.biopharmawatch.com/news/ROVA/altrova-health-exclusive-distribution-agreement-us BiopharmaWatch en 2026-09-08T11:07:00.000Z Altrova Health Signs Exclusive U.S. Distribution Agreement to Launch Its Detection and Wellness Portfolio Across the United States https://www.biopharmawatch.com/news/HLF/herbalife-250-million-share-repurchase-program BiopharmaWatch en 2026-09-08T11:05:00.000Z Herbalife Announces $250 Million Share Repurchase Program https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-obexelimab-ig4-rd-event BiopharmaWatch en 2026-09-08T11:05:00.000Z Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event https://www.biopharmawatch.com/news/IVVD/invivyd-participate-september-investor-conferences BiopharmaWatch en 2026-09-08T11:01:00.000Z Invivyd to Participate in Upcoming September Investor Conferences https://www.biopharmawatch.com/news/VOR/vor-completes-enrollment-upstream-mg-trial BiopharmaWatch en 2026-09-08T11:00:35.000Z Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-fda-type-c-meeting-outcome BiopharmaWatch en 2026-09-08T11:00:22.000Z X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-appoints-keith-lane-executive-vice-president BiopharmaWatch en 2026-09-08T11:00:00.000Z Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs https://www.biopharmawatch.com/news/UTHR/united-therapeutics-accelerated-share-repurchase-agreement BiopharmaWatch en 2026-09-08T11:00:00.000Z United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-breakthrough-therapy-dt120-mdd BiopharmaWatch en 2026-09-08T11:00:00.000Z Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results https://www.biopharmawatch.com/news/CGEN/compugen-fireside-chat-hc-wainwright-conference BiopharmaWatch en 2026-09-08T11:00:00.000Z Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/PLSM/pulsenmore-expands-fertility-care-home-ultrasound-system BiopharmaWatch en 2026-09-08T11:00:00.000Z Pulsenmore Expands into Fertility Care: Completes CE European Registration of Home Ultrasound System for Follicular Monitoring https://www.biopharmawatch.com/news/KURA/kura-oncology-appoints-jennifer-fulk-cfo BiopharmaWatch en 2026-09-08T11:00:00.000Z Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer https://www.biopharmawatch.com/news/ANL/adlai-nortye-first-patient-dosed-an4035-trial BiopharmaWatch en 2026-09-08T11:00:00.000Z Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-promotes-thomas-englese-cc BiopharmaWatch en 2026-09-08T11:00:00.000Z Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer https://www.biopharmawatch.com/news/GLUE/monte-rosa-phase-2-study-sjogrens-disease BiopharmaWatch en 2026-09-08T11:00:00.000Z Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391) https://www.biopharmawatch.com/news/CALC/calcimedica-hc-wainwright-investment-conference-2026 BiopharmaWatch en 2026-09-08T11:00:00.000Z CalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/ERAS/erasca-morgan-stanley-healthcare-conference-2026 BiopharmaWatch en 2026-09-08T11:00:00.000Z Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-morgan-stanley-conference-2026 BiopharmaWatch en 2026-09-08T11:00:00.000Z Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/TLRY/brewdog-leicester-tigers-partnership-2026 BiopharmaWatch en 2026-09-08T11:00:00.000Z BrewDog Roars into Rugby with Five-Year Leicester Tigers Partnership, Bringing Punk Energy to Welford Road https://www.biopharmawatch.com/news/OKYO/okyo-pharma-cantor-global-healthcare-conference-2026 BiopharmaWatch en 2026-09-08T11:00:00.000Z OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference https://www.biopharmawatch.com/news/NKTX/nkarta-present-initial-autoimmune-clinical-data-acr-2026 BiopharmaWatch en 2026-09-08T11:00:00.000Z Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026 https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-investor-conferences-september-2026 BiopharmaWatch en 2026-09-08T11:00:00.000Z NRx Pharmaceuticals to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/EDIT/editas-medicine-appoints-dan-ory-cmo BiopharmaWatch en 2026-09-08T11:00:00.000Z Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer https://www.biopharmawatch.com/news/NBP/novabridge-appoints-martin-dewhurst-board-directors BiopharmaWatch en 2026-09-08T11:00:00.000Z NovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent Director https://www.biopharmawatch.com/news/BMY/bms-quintessential-trial-results-arlocabtagene BiopharmaWatch en 2026-09-08T10:59:00.000Z Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ... https://www.biopharmawatch.com/news/PHVS/pharvaris-chapter-3-study-positive-results BiopharmaWatch en 2026-09-08T10:50:00.000Z Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks https://www.biopharmawatch.com/news/MRK/merck-participate-morgan-stanley-healthcare-conference BiopharmaWatch en 2026-09-08T10:45:00.000Z Merck to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-september-2026-investor-conferences BiopharmaWatch en 2026-09-08T10:45:00.000Z Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences https://www.biopharmawatch.com/news/TFX/teleflex-appoints-sean-salmon-board-directors BiopharmaWatch en 2026-09-08T10:30:00.000Z Teleflex Appoints Veteran Medical Technology Executive Sean M. Salmon to Teleflex Board of Directors https://www.biopharmawatch.com/news/HSIC/henry-schein-investor-conference-september-2026 BiopharmaWatch en 2026-09-08T10:30:00.000Z Henry Schein to Participate in Upcoming Investor Conference in September https://www.biopharmawatch.com/news/CMPS/compass-pathways-hcp-education-campaign-psych-congress-2026 BiopharmaWatch en 2026-09-08T10:30:00.000Z Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026 https://www.biopharmawatch.com/news/CAI/caris-life-sciences-launches-national-campaign-early-cancer-detection BiopharmaWatch en 2026-09-08T10:30:00.000Z Caris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise Awareness of Early Cancer Detection and Caris Detect https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-lovell-partnership-federal-healthcare BiopharmaWatch en 2026-09-08T10:30:00.000Z Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets https://www.biopharmawatch.com/news/EXOZ/exozymes-curia-manufacturing-partner-nct BiopharmaWatch en 2026-09-08T10:20:00.000Z eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT https://www.biopharmawatch.com/news/BEAM/beam-302-phase-1-2-trial-update-ers-congress-2026 BiopharmaWatch en 2026-09-08T10:00:35.000Z Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 https://www.biopharmawatch.com/news/OSTX/os-therapies-ost-her2-phase-2b-trial-results BiopharmaWatch en 2026-09-08T10:00:00.000Z OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial https://www.biopharmawatch.com/news/RDNT/radnet-presentation-jefferies-conference-september-2026 BiopharmaWatch en 2026-09-08T10:00:00.000Z RadNet, Inc. to Present at the Jefferies Healthcare Services and Technology Conference on September 15, 2026 https://www.biopharmawatch.com/news/MNOV/medicinova-investor-conferences-september-2026 BiopharmaWatch en 2026-09-08T10:00:00.000Z MediciNova to Participate in Two Investor Conferences in September https://www.biopharmawatch.com/news/GMAB/extraordinary-general-meeting-genmab-october-2026 BiopharmaWatch en 2026-09-08T10:00:00.000Z Notice to Convene an Extraordinary General Meeting of Genmab A/S https://www.biopharmawatch.com/news/ROIV/pulmovant-positive-results-phocus-study-mosliciguat BiopharmaWatch en 2026-09-08T10:00:00.000Z Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study https://www.biopharmawatch.com/news/BLTE/belite-bio-submission-new-drug-application-japan BiopharmaWatch en 2026-09-08T10:00:00.000Z Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1 https://www.biopharmawatch.com/news/STME/stimcell-engages-stonegate-capital-markets-advisor BiopharmaWatch en 2026-09-08T09:15:00.000Z StimCell Energetics Engages Stonegate Capital Markets as Non-Exclusive Advisor for Strategic Capital Market Transactions https://www.biopharmawatch.com/news/JAGX/neonorm-dog-jaguar-health-amazon-launch BiopharmaWatch en 2026-09-08T09:00:00.000Z Now Available on Amazon: Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs https://www.biopharmawatch.com/news/SNN/smith-nephew-cash-tender-offer-2030-bonds BiopharmaWatch en 2026-09-08T08:40:00.000Z Smith & Nephew Plc Announces Cash Tender Offer for 2030 Bonds Up To $250m https://www.biopharmawatch.com/news/NNVC/clinical-trial-nv-387-ebola-drc BiopharmaWatch en 2026-09-08T08:30:00.000Z Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo https://www.biopharmawatch.com/news/MODD/modular-medical-iaccess-alpha-conference-2026 BiopharmaWatch en 2026-09-08T08:00:00.000Z Modular Medical to Participate in the iAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 on September 15-16, 2026 https://www.biopharmawatch.com/news/UPB/upstream-bio-phase-2-valiant-trial-verekitug-asthma BiopharmaWatch en 2026-09-08T07:30:00.000Z Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026 https://www.biopharmawatch.com/news/DTC/defence-therapeutics-ceo-shareholder-letter BiopharmaWatch en 2026-09-08T07:15:00.000Z Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders https://www.biopharmawatch.com/news/MEDS/datameds-ai-tollo-health-nfl-alumni-partnership BiopharmaWatch en 2026-09-08T06:00:00.000Z Datameds, AI., and Tollo Health Partner with the NFL Alumni Association for Health Lives Here National Campaign Rollout https://www.biopharmawatch.com/news/NVS/novartis-delpacibart-etedesiran-phase-iii-harbor-study-update BiopharmaWatch en 2026-09-08T05:00:00.000Z Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1) https://www.biopharmawatch.com/news/BNXT/bionxt-sublingual-everolimus-odf-study BiopharmaWatch en 2026-09-08T03:05:00.000Z BioNxt Advances Sublingual Everolimus ODF for Organ Transplant Rejection with Initiation of Large-Animal Pharmacokinetic Study https://www.biopharmawatch.com/news/GENFF/genflow-biosciences-slabs-trial-success BiopharmaWatch en 2026-09-08T02:00:00.000Z Genflow Biosciences PLC Announces Primary Endpoint in SLAB Clinical Trial Met https://www.biopharmawatch.com/news/JNJ/jnj-neuropsychiatry-data-psych-congress-2026 BiopharmaWatch en 2026-09-08T00:00:00.000Z Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026 Johnson & Johnson (NYSE: JNJ) today announced that 24 abstracts featuring clinical data and real-world evidence across the neuropsychiatry portfolio... https://www.biopharmawatch.com/news/BHC/bausch-health-expansion-mexico-emea-markets BiopharmaWatch en 2026-09-08T00:00:00.000Z Bausch Health a YUN oznamují expanzi do Mexika a na nové trhy v regionu EMEA Společnost Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), globální diverzifikovaná farmaceutická společnost, a belgická firma YUN, průkopník v... https://www.biopharmawatch.com/news/BHC/bausch-health-expansion-mexico-emea BiopharmaWatch en 2026-09-08T00:00:00.000Z Bausch Health a YUN ohlasujú expanziu do Mexika a na ďalšie trhy v regióne EMEA Spoločnosť Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), globálny diverzifikovaný farmaceutický výrobca, a YUN, belgický inovátor v oblasti... https://www.biopharmawatch.com/news/INBX/inhibrx-inbrx-106-phase-2-hnscc-study-results BiopharmaWatch en 2026-09-08T00:00:00.000Z Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study First OX40 agonist to demonstrate clinical benefit in a randomized study INBRX-106 plus pembrolizumab delivers a 48.3% cORR and 72.4% of patients... https://www.biopharmawatch.com/news/BHC/bausch-health-yun-expansion-mexico-emea-markets BiopharmaWatch en 2026-09-08T00:00:00.000Z Bausch Health and YUN Announce Expansion to Mexico and Across Additional EMEA Markets Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), a global, diversified pharmaceutical company, and YUN, a Belgian innovator in pioneering... https://www.biopharmawatch.com/news/BHC/bausch-health-expands-into-mexico-and-emea-markets BiopharmaWatch en 2026-09-08T00:00:00.000Z Bausch Health i YUN ogłaszają ekspansję na rynek meksykański oraz kolejne rynki regionu EMEA Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), globalne, zdywersyfikowane przedsiębiorstwo farmaceutyczne, oraz YUN, belgijski innowator w...